• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Elicio Therapeutics, Inc. - Common Stock (NQ:ELTX)

    3.850 -0.860 (-18.26%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,349,660
    Open 4.210
    Bid (Size) 3.900 (200)
    Ask (Size) 3.960 (300)
    Prev. Close 4.710
    Today's Range 3.660 - 4.550
    52wk Range 2.660 - 16.00
    Shares Outstanding 29,798,399
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Which stocks have an unusual volume on Thursday? ↗
    Via Chartmill
    These stocks that are showing activity before the opening bell on Thursday. ↗
    Via Chartmill

    Performance

    YTD
    -52.2%
    -52.2%
    1 Month
    -59.8%
    -59.8%
    3 Month
    -67.0%
    -67.0%
    6 Month
    -51.1%
    -51.1%
    1 Year
    -51.6%
    -51.6%

    More News

    Read More
    Which stocks are moving after the closing bell on Wednesday? ↗
    Via Chartmill
    Top movers in Wednesday's session ↗
    Via Chartmill
    Elicio Therapeutics (NASDAQ:ELTX) Q1 2026 Results Show Extended Cash Runway Ahead of Key Phase 2 Data Readout ↗
    Via Chartmill
    News headline image
    Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    Monday's session: top gainers and losers ↗
    Via Chartmill
    Gapping stocks in Monday's session ↗
    Via Chartmill
    Monday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics to Present at the Bank of America Healthcare Conference
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Inducement Grants
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Inducement Grants
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Inducement Grants
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Inducement Grants
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Inducement Grants
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
    From Elicio Therapeutics Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Elicio Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Elicio Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Elicio Therapeutics, Inc. - Common Stock trade on?
    Elicio Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Elicio Therapeutics, Inc. - Common Stock?
    The ticker symbol for Elicio Therapeutics, Inc. - Common Stock is ELTX on the Nasdaq Stock Market
    What is the current price of Elicio Therapeutics, Inc. - Common Stock?
    The current price of Elicio Therapeutics, Inc. - Common Stock is 3.850
    When was Elicio Therapeutics, Inc. - Common Stock last traded?
    The last trade of Elicio Therapeutics, Inc. - Common Stock was at 06/18/26 04:00 PM ET
    What is the market capitalization of Elicio Therapeutics, Inc. - Common Stock?
    The market capitalization of Elicio Therapeutics, Inc. - Common Stock is 114.72M
    How many shares of Elicio Therapeutics, Inc. - Common Stock are outstanding?
    Elicio Therapeutics, Inc. - Common Stock has 115M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.